The ChEMBL database in 2017

Nucleic Acids Research

Volumn 45, Issue D1, 2017, Pages D945-D954

  Gaulton, Anna ^a   Hersey, Anne ^a   Nowotka, Micha L ^a   Patricia Bento, A ^a,b   Chambers, Jon ^a   Mendez, David ^a   Mutowo, Prudence ^a   Atkinson, Francis ^a   Bellis, Louisa J ^a,c   Cibrian Uhalte, Elena ^a   Davies, Mark ^a,d   Dedman, Nathan ^a,e   Karlsson, Anneli ^a,d   Magarinos, Maŕia Paula ^a,b   Overington, John P ^a,d   Papadatos, George ^a,f   Smit, Ines ^a   Leach, Andrew R ^a  

^a EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^b Wellcome Genome Campus   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d BenevolentAI   (United Kingdom)

^e Local Measure   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; ASSAY; BIOLOGICAL ACTIVITY; CALCULATION; CHEMICAL DATABASE; COMPUTER INTERFACE; CROP PROTECTION; DATA EXTRACTION; DRUG ACTIVITY; DRUG DATABASE; DRUG DISPOSITION; DRUG INDICATION; DRUG METABOLISM; DRUG TARGETING; DRUG TOXICITY; EMBL NUCLEOTIDE SEQUENCE DATABASE; HUMAN; INFORMATION SERVICE; MEDICINAL CHEMISTRY; NEGLECTED DISEASE; NONHUMAN; ODONTOLOGY; PATENT; SCREENING; STRUCTURE ANALYSIS; BIOLOGY; DRUG DEVELOPMENT; GENE ONTOLOGY; MOLECULAR GENETICS; NUCLEIC ACID DATABASE; PHARMACOLOGY; PROCEDURES; SEARCH ENGINE; WEB BROWSER;

COMPUTATIONAL BIOLOGY; CROP PROTECTION; DATABASES, CHEMICAL; DATABASES, NUCLEIC ACID; DRUG DISCOVERY; GENE ONTOLOGY; HUMANS; MOLECULAR SEQUENCE ANNOTATION; PHARMACOLOGY; SEARCH ENGINE; USER-COMPUTER INTERFACE; WEB BROWSER;

EID: 85016137105     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkw1074     Document Type: Article

References (58)

1. Bento, A.P., Gaulton, A., Hersey, A., Bellis, L.J., Chambers, J., Davies, M., Kruger, F.A., Light, Y., Mak, L., McGlinchey, S. et al. (2014) The ChEMBL bioactivity database: an update. Nucleic Acids Res., 42, D1083-D1090.
2. Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B. et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 40, D1100-D1107.
3. Arrowsmith, J. and Miller, P. (2013) Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov., 12, 569.
4. Bunnage, M.E. (2011) Getting pharmaceutical R&D back on target. Nat. Chem. Biol., 7, 335-339.
5. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C. and Rosenthal, J. (2014) Clinical development success rates for investigational drugs. Nat. Biotechnol., 32, 40-51.
6. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 3, 711-715.
7. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G. and Pangalos, M.N. (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a fve-dimensional framework. Nat. Rev. Drug Discov., 13, 419-431.
8. Waring, M.J., Arrowsmith, J., Leach, A.R., Leeson, P.D., Mandrell, S., Owen, R.M., Pairaudeau, G., Pennie, W.D., Pickett, S.D., Wang, J. et al. (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov., 14, 475-486.
9. Morgan, P., Van Der Graaf, P.H., Arrowsmith, J., Feltner, D.E., Drummond, K.S., Wegner, C.D. and Street, S.D. (2012) Can the fow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today, 17, 419-424.
10. Papadatos, G., Davies, M., Dedman, N., Chambers, J., Gaulton, A., Siddle, J., Koks, R., Irvine, S.A., Pettersson, J., Goncharoff, N. et al. (2016) SureChEMBL: a large-scale, chemically annotated patent document database. Nucleic Acids Res., 44, D1220-D1228.
11. Gilson, M.K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L. and Chong, J. (2016) BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res., 44, D1045-D1053.
12. Gamo, F.J., Sanz, L.M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.L., Vanderwall, D.E., Green, D.V., Kumar, V., Hasan, S. et al. (2010) Thousands of chemical starting points for antimalarial lead identifcation. Nature, 465, 305-310.
13. Ioset, J.R. and Chang, S. (2011) Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges. Future Med. Chem., 3, 1361-1371.
14. Orti, L., Carbajo, R.J., Pieper, U., Eswar, N., Maurer, S.M., Rai, A.K., Taylor, G., Todd, M.H., Pineda-Lucena, A., Sali, A. et al. (2009) A kernel for open source drug discovery in tropical diseases. PLoS Negl. Trop. Dis., 3, e418.
15. Spangenberg, T., Burrows, J.N., Kowalczyk, P., McDonald, S., Wells, T.N. and Willis, P. (2013) The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One, 8, e62906.
16. Gaulton, A., Kale, N., van Westen, G.J., Bellis, L.J., Bento, A.P., Davies, M., Hersey, A., Papadatos, G., Forster, M., Wege, P. et al. (2015) A large-scale crop protection bioassay data set. Sci. Data, 2, 150032.
17. Ceccarelli, S.M., Chomienne, O., Gubler, M. and Arduini, A. (2011) Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research. J. Med. Chem., 54, 3109-3152.
18. Kaiser, D., Terfoth, L., Kopp, S., Schulz, J., de Laet, R., Chiba, P., Ecker, G.F. and Gasteiger, J. (2007) Self-organizing maps for identifcation of new inhibitors of P-glycoprotein. J. Med. Chem., 50, 1698-1702.
19. Lee, J.A., Uhlik, M.T., Moxham, C.M., Tomandl, D. and Sall, D.J. (2012) Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem., 55, 4527-4538.
20. Abeyruwan, S., Vempati, U.D., Kucuk-McGinty, H., Visser, U., Koleti, A., Mir, A., Sakurai, K., Chung, C., Bittker, J.A., Clemons, P.A. et al. (2014) Evolving BioAssay Ontology (BAO): modularization, integration and applications. J. Biomed. Semantics, 5, S5.
21. Visser, U., Abeyruwan, S., Vempati, U., Smith, R.P., Lemmon, V. and Schurer, S.C. (2011) BioAssay Ontology (BAO): a semantic description of bioassays and high-throughput screening results. BMC Bioinformatics, 12, 257.
22. Gkoutos, G.V., Schofeld, P.N. and Hoehndorf, R. (2012) The Units Ontology: a tool for integrating units of measurement in science. Database (Oxford), 2012, bas033.
23. Sarntivijai, S., Lin, Y., Xiang, Z., Meehan, T.F., Diehl, A.D., Vempati, U.D., Schurer, S.C., Pang, C., Malone, J., Parkinson, H. et al. (2014) CLO: The cell line ontology. J. Biomed. Semantics, 5, 37.
24. Malone, J., Holloway, E., Adamusiak, T., Kapushesky, M., Zheng, J., Kolesnikov, N., Zhukova, A., Brazma, A. and Parkinson, H. (2010) Modeling sample variables with an experimental factor ontology. Bioinformatics, 26, 1112-1118.
25. Vempati, U.D., Chung, C., Mader, C., Koleti, A., Datar, N., Vidovic, D., Wrobel, D., Erickson, S., Muhlich, J.L., Berriz, G. et al. (2014) Metadata standard and data exchange specifcations to describe, model, and integrate complex and diverse high-throughput screening data from the library of integrated network-based cellular signatures (LINCS). J. Biomol. Screen., 19, 803-816.
26. Mungall, C.J., Torniai, C, Gkoutos, G.V, Lewis, S.E. and Haendel, M.A. (2012) Uberon, an integrative multi-species anatomy ontology. Genome Biol, 13, R5.
27. Gremse, M., Chang, A., Schomburg, I., Grote, A., Scheer, M., Ebeling, C. and Schomburg, D. (2011) The BRENDA Tissue Ontology (BTO): the frst all-integrating ontology of all organisms for enzyme sources. Nucleic Acids Res., 39, D507-D513.
28. Southan, C, Sharman, J.L., Benson, H.E., Faccenda, E., Pawson, A.J., Alexander, S.P., Buneman, O.P., Davenport, A.P., McGrath, J.C, Peters, J.A. et al (2016) The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res., 44, D1054-D1068.
29. Saier, M.H. Jr, Reddy, V.S., Tsu, B.V., Ahmed, M.S., Li, C. and Moreno-Hagelsieb, G (2016) The Transporter Classifcation Database (TCDB): recent advances. Nucleic Acids Res., 44, D372-D379.
30. Shah, M.A., Denton, E.L., Liu, L. and Schapira, M. (2014) ChromoHub V2: cancer genomics. Bioinformatics, 30, 590-592.
31. Mutowo, P, Bento, A.P, Dedman, N, Gaulton, A., Hersey, A., Lomax, J. and Overington, J.P (2016) A drug target slim: using Gene Ontology and Gene Ontology annotations to navigate protein-ligand target space in ChEMBL. J. Biomed. Semantics, 7, 59.
32. WHO Collaborating Centre for Drug Statistics Methodology. (2015) Guidelines for ATC classifcation and DDD assignment 2015. WHO Collaborating Centre for Drug Statistics Methodology, Oslo.
33. Huston, M.W., Williams, R.J., Bergeris, A., Fun, J. and Tse, T (2012) New style and new content for ClinicalTrials.gov. NLM Tech. Bull, 387, e5.
34. Nunes, T, Campos, D, Matos, S. and Oliveira, J.L. (2013) BeCAS: biomedical concept recognition services and visualization. Bioinformatics, 29, 1915-1916.
35. Siramshetty, V.B., Nickel, J., Omieczynski, C, Gohlke, B.O., Drwal, M.N. and Preissner, R. (2016) WITHDRAWN-a resource for withdrawn and discontinued drugs. Nucleic Acids Res., 44, D1080-D1086.
36. Bakke, O.M., Manocchia, M., de Abajo, F., Kaitin, K.I. and Lasagna, L. (1995) Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin. Pharmacol Ther, 58, 108-117.
37. Qureshi, Z.P, Seoane-Vazquez, E., Rodriguez-Monguio, R., Stevenson, K.B. and Szeinbach, S.L. (2011) Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol. Drug Saf., 20, 772-777.
38. Fung, M., Thornton, A., Mybeck, K., Wu, J.H., Hornbuckle, K. and Muniz, E. (2001) Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inf. J., 35, 293-317.
39. Turner, E.H. (2013) How to access and process FDA drug approval packages for use in research. BMJ, 347, f5992.
40. Foti, R.S. and Dalvie, D.K. (2016) Cytochrome P450 and Non-Cytochrome P450 oxidative metabolism: Contributions to the pharmacokinetics, safety, and effcacy of xenobiotics. Drug Metab. Dispos., 44, 1229-1245.
41. Kalgutkar, A.S., Gardner, I., Obach, R.S., Shaffer, CL., Callegari, E., Henne, K.R., Mutlib, A.E., Dalvie, D.K., Lee, J.S., Nakai, Y. et al (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab., 6, 161-225.
42. Blake, J.F. (2005) Identifcation and evaluation of molecular properties related to preclinical optimization and clinical fate. Med. Chem., 1, 649-655.
43. Hann, M., Hudson, B., Lewell, X., Lifely, R., Miller, L. and Ramsden, N. (1999) Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci., 39, 897-902.
44. Pearce, B.C, Sofa, M.J., Good, A.C, Drexler, DM. and Stock, D.A. (2006) An empirical process for the design of high-throughput screening deck flters. J. Chem. Inf. Model, 46, 1060-1068.
45. Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I.H, Frearson, J. and Wyatt, PG (2008) Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem, 3, 435-444.
46. Baell, J.B. and Holloway, GA. (2010) New substructure flters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem., 53, 2719-2740.
47. Ochoa, R., Davies, M., Papadatos, G., Atkinson, F. and Overington, J.P. (2014) myChEMBL: a virtual machine implementation of open data and cheminformatics tools. Bioinformatics, 30, 298-300.
48. Davies, M., Nowotka, M., Papadatos, G., Atkinson, F., van Westen, G.J., Dedman, N., Ochoa, R. and Overington, J.P. (2014) MyChEMBL: a virtual platform for distributing cheminformatics tools and open data. Challenges, 5, 334-337.
49. Filippov, I.V. and Nicklaus, M.C. (2009) Optical structure recognition software to recover chemical information: OSRA, an open source solution. J. Chem. Inf. Model, 49, 740-743.
50. O'Boyle, N.M., Banck, M., James, C.A., Morley, C, Vandermeersch, T. and Hutchison, G.R. (2011) Open babel: an open chemical toolbox. J. Cheminform., 3, 33.
51. Davies, M., Nowotka, M., Papadatos, G, Dedman, N., Gaulton, A., Atkinson, F., Bellis, L. and Overington, J.P (2015) ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res., 43, W612-W620.
52. Wang, Y, Cheng, T., Wang, J., Gindulyte, A., Shoemaker, B.A., Thiessen, PA., He, S., Zhang, J. and Bryant, S.H. (2016) PubChem BioAssay: 2017 update. Nucleic Acids Res., doi:10.1093/nar/gkw1118.
53. Tym, J.E., Mitsopoulos, C, Coker, E.A., Razaz, P, Schierz, A.C, Antolin, A.A. and Al-Lazikani, B. (2016) canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic Acids Res., 44, D938-D943.
54. Williams, A.J., Harland, L., Groth, P., Pettifer, S., Chichester, C., Willighagen, E.L., Evelo, C.T., Blomberg, N., Ecker, G., Goble, C. et al. (2012) Open PHACTS: semantic interoperability for drug discovery. Drug Discov. Today, 17, 1188-1198.
55. Koscielny, G., An, P., Carvalho-Silva, D., Cham, J.A., Munoz-Pomer Fuentes, A., Fumis, L., Gasparyan, R., Hasan, S., Karamanis, N., Maguire, M. et al. (2016) Open targets: a platform for therapeutic target identifcation and validation. Nucleic Acids Res., doi:10.1093/nar/gkw1055.
56. Nguyen, D.T., Mathias, D., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L., Karlsson, A. et al. (2016) Pharos: collating protein information to shed light on the druggable genome. Nucleic Acids Res., doi:10.1093/nar/gkw1072.
57. Chambers, J., Davies, M., Gaulton, A., Papadatos, G., Hersey, A. and Overington, J.P. (2014) UniChem: extension of InChI-based compound mapping to salt, connectivity and stereochemistry layers. J. Cheminform., 6, 43.
58. Papadatos, G., Gaulton, A., Hersey, A. and Overington, J.P. (2015) Activity, assay and target data curation and quality in the ChEMBL database. J. Comput. Aided Mol. Des., 29, 885-896.